Neurobehavioral & Psychiatry Core

项目总结/摘要：神经行为和精神病学核心 神经行为和精神病学（NBP）核心，以前的神经行为单位 上一个资助期的神经评估核心是为竞争HNRC更新提出的新核心。 新的NBP核心将应用评估专业知识进行全面的神经心理学， 精神病（包括精神病诊断和维度症状水平）、物质使用和日常生活 功能评估。这支持了该中心对神经行为表型的新重视， 艾滋病毒感染者（PWH），并将其与其他HNRC核心和相关的医学和生物数据联系起来 问题研究NBP的目标直接映射到艾滋病研究优先事项办公室的主要主题“艾滋病毒- 相关的合并症、合并感染和并发症”通过解决神经系统后果的领域， 精神疾病和健康差距。NBP核心的目标是帮助确定 有证据表明认知、抑郁和日常功能发生变化的个人，并提供 全面的纵向神经认知、精神、物质使用和日常功能评估 在威尔斯亲王医院和艾滋病病毒对照组中。重要的是，我们的核心将提供神经心理学和 精神病学（包括抑郁症）评估，以确定神经行为表型。我们的目标是 通过提供一系列服务、培训和 为一些项目提供科学咨询，如由干扰器驱动的R 01 s、R21 s和R34 s，国际神经艾滋病病毒 研究，以及各种内部和外部调查。从历史上看，NBP核心及其调查人员 一直是neuroHIV领域的国家和国际领导者，推动了国际和国际艾滋病研究的发展。 协调评估和新方法，同时适应不断发展的科学环境。 我们打算在这方面继续努力。此外，为了支持HNRC更加注重合并 PWH中的神经行为表型，以及随时间变化的参与者，NBP核心将管理 更详细的精神病评估，将检查抑郁症的详细组成部分（例如，快感缺乏， 冷漠）、焦虑、压力、不良童年事件和生活创伤，以及复原力和社会支持。所有这些 因素可能影响神经认知，抑郁症，艾滋病和其他疾病之间的复杂关系。 临床结果。我们将与1）神经医学核心携手合作，以确定潜在的生物学 神经行为表型的机制，探索与HIV疾病的联系（例如，CSF病毒载量）， 炎性过程/生物标志物（例如，IL-6）、其他医学合并症（例如，代谢综合征），共- 感染（例如，CMV; NM和NVB核心）;和2）MIBI核心，以探索微生物组和 代谢组对神经行为结果和/或表型的影响;以及NM和NVB核心关于 神经炎症和抗逆转录病毒药物的长期保护和/或神经毒性作用。

PROJECT SUMMARY/ABSTRACT: NEUROBEHAVIORAL AND PSYCHIATRY CORE The NeuroBehavioral and Psychiatry (NBP) Core, previously the Neurobehavioral Unit of the NeuroAssessment Core from the prior funding period, is a new Core proposed for the competing HNRC renewal. The new NBP Core will apply assessment expertise in conducting comprehensive neuropsychological, psychiatric (including both psychiatric diagnoses and dimensional symptom levels), substance use, and daily functioning assessments. This supports the Center’s new emphasis on neurobehavioral phenotypes among persons with HIV (PWH), and links them to medical and biological data from other HNRC Cores and associated studies. NBP aims map directly onto the Office of AIDS Research Priorities under the major topic of “HIV- associated comorbidities, coinfections, and complications” by addressing areas of neurologic consequences, mental illness, and health disparities. The goals of the NBP Core are to contribute to the identification of individuals who have evidenced changes in cognition, depression and daily functioning, and to provide comprehensive longitudinal neurocognitive, psychiatric, substance use and everyday functioning assessments on the PWH and HIV- comparison participants. Importantly, our core will provide the neuropsychological and psychiatric (including depression) assessments in order to determine neurobehavioral phenotypes. We aim to facilitate and enhance multidisciplinary research in neuroHIV by providing a range of services, training and scientific consultation to projects such as investigator-driven R01s, R21s, and R34s, international neuroHIV studies, and a variety of intra- and extramural investigations. Historically, the NBP Core and its investigators have been national and international leaders in the neuroHIV field, spurring the development of both international harmonization of assessments and new methods, while adapting to the continually evolving scientific landscape. We aim to continue in this regard. In addition, in support of the HNRC’s increased focus on combined neurobehavioral phenotypes among PWH, and participants who change over time, the NBP Core will administer a more detailed psychiatric assessment which will examine detailed components of depression (e.g., anhedonia, apathy), anxiety, stress, adverse childhood events and life trauma, and resilience and social support. All of these factors may influence the complex relationships among neurocognition, depression, HIV disease and other clinical outcomes. We will work hand-in-hand with 1) the NeuroMedical Core to identify underlying biological mechanisms of neurobehavioral phenotypes, exploring connections to HIV disease (e.g., CSF viral load), inflammatory processes/biomarkers (e.g., IL-6), other medical comorbidities (e.g., metabolic syndrome), co- infections (e.g., CMV; NM and NVB Cores); and 2) with the MIBI Core to explore effects of microbiome and metabolome on neurobehavioral outcomes and/or phenotypes; and with both NM and NVB Cores regarding neuroinflammation and long-term protective and/or neurotoxic effects of antiretrovirals.